- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Adoptive transfer.
Displaying page 1 of 1.
EudraCT Number: 2005-001092-35 | Sponsor Protocol Number: 10 | Start Date*: 2006-11-08 |
Sponsor Name: | ||
Full Title: Adoptive Immuntherapie der akuten ADV-Infektion nach allogener Knochenmark- oder peripherer Blutstammzelltransplantation | ||
Medical condition: Adenovirus infection following allogeneic stem cell transplantation. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001335-31 | Sponsor Protocol Number: virus-specific_CD8_T-cells_001 | Start Date*: 2013-11-08 |
Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta | ||
Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation | ||
Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002941-36 | Sponsor Protocol Number: M11TCR | Start Date*: 2012-04-02 | |||||||||||
Sponsor Name:NKI-AVL | |||||||||||||
Full Title: Multicenter phase 1/2a study using T-cell receptor gene therapy in metastatic melanoma | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001929-27 | Sponsor Protocol Number: NK4AML | Start Date*: 2020-05-20 |
Sponsor Name:Radboud University Medical Centre | ||
Full Title: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study’ | ||
Medical condition: AML patients who do not have rapid progressive disease with or without disease controlling medication and who are not eligible for allogeneic SCT. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001731-31 | Sponsor Protocol Number: YFV_001 | Start Date*: 2019-09-02 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Cytotoxicity of Yellow Fever specific CD8 T cells Following YF-17D Vaccination | |||||||||||||
Medical condition: Healthy individuals or HIV-1 infected individuals | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007612-29 | Sponsor Protocol Number: UCL/09/0050 | Start Date*: 2013-02-26 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia | |||||||||||||
Medical condition: The medical condition under investigation is childhood precursor B acute lymphoblastic leukaemia (ALL). | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000657-31 | Sponsor Protocol Number: EMCR2015-7741 | Start Date*: 2019-09-05 | ||||||||||||||||||||||||||
Sponsor Name:Erasmus MC Cancer Institute | ||||||||||||||||||||||||||||
Full Title: Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer. | ||||||||||||||||||||||||||||
Medical condition: unresectable stage IIIc and IV melanoma (including unknown primary, mucosal and uveal melanoma), and unresectable recurrent/metastatic(R/M) HNSCC. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004888-31 | Sponsor Protocol Number: 208750 | Start Date*: 2020-01-27 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline research & development Ltd. | ||||||||||||||||||||||||||||
Full Title: Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies | ||||||||||||||||||||||||||||
Medical condition: Synovial sarcoma Multiple myeloma Non-small cell lung cancer Myxoid liposarcoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) SE (Completed) IT (Trial now transitioned) FR (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004682-11 | Sponsor Protocol Number: AUTO3-DB1 | Start Date*: 2017-07-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Autolus Limited | |||||||||||||||||||||||||||||||||
Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 with Anti PD-1 Antibody in Patients wi... | |||||||||||||||||||||||||||||||||
Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL) and large B cell lymphoma subsets | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006649-18 | Sponsor Protocol Number: 08/0214 | Start Date*: 2011-11-16 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy with CMV TCR-transduced Donor-derived T cells for Recipients of Allogeneic Haematopoietic Stem Cell ... | |||||||||||||
Medical condition: CMV reactivation/infection in post allogeneic haematopoietic stem cell transplant recipients. Allo-HSCT being performed for underlying haematological malignancy (eg, AML, ALL, NHL, Hodgkin Lymphoma... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001264-30 | Sponsor Protocol Number: CARAMBA-1 | Start Date*: 2020-03-11 | |||||||||||
Sponsor Name:Universitätsklinikum Würzburg | |||||||||||||
Full Title: A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma | |||||||||||||
Medical condition: Multiple myeloma (MM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
